{"schema_version":"1.0","hypothesis_id":4982,"triple":{"drug":"erlotinib","drug_canonical":"erlotinib","mediator":"EGFR","mediator_canonical":"EGFR","outcome":"Alzheimer's disease","outcome_canonical":"Alzheimer disease"},"domain":{"domain":"cross_domain","source":"pancreatic_cancer","target":"alzheimer"},"provenance_completeness":"partial_backfill","completeness_notes":"Backfilled retroactively from DB state on 2026-05-13. The pipeline_run this row references was created by the backfill script, not by the actual generation orchestrator. Source papers, claims, scoring, and embedding config are recovered; generation-time metadata (exact git commit at gen time, host, exact command) is not recoverable.","source_papers":[{"doi":"10.1111/acel.14330","pmid":"39252463","year":2024,"roles":["mediator_outcome"],"title":"Plasma proteomics for risk prediction of Alzheimer's disease in the general population","journal":"Aging Cell","work_id":67774,"publication_date":"2024-09-09"},{"doi":"10.1200/jco.22.02770","pmid":"37847995","year":2023,"roles":["drug_mediator"],"title":"Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group","journal":"J Clin Oncol","work_id":163119,"publication_date":"2023-10-17"},{"doi":"10.21037/jgo-22-327","pmid":"36092320","year":2022,"roles":["drug_mediator"],"title":"A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer","journal":"J Gastrointest Oncol","work_id":173558,"publication_date":"2022-07-27"},{"doi":"10.1016/j.ebiom.2021.103327","pmid":"33862582","year":2021,"roles":["drug_mediator"],"title":"A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial","journal":"EBioMedicine","work_id":170142,"publication_date":"2021-04-01"},{"doi":"10.1074/jbc.ra120.014126","pmid":"33148698","year":2020,"roles":["drug_mediator"],"title":"Glycosyltransferase ST6Gal-I promotes the epithelial to mesenchymal transition in pancreatic cancer cells","journal":"J Biol Chem","work_id":71894,"publication_date":"2020-11-04"},{"doi":"10.1634/theoncologist.2018-0878","pmid":"30679315","year":2019,"roles":["drug_mediator"],"title":"A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)","journal":"Oncologist","work_id":74740,"publication_date":"2019-01-24"},{"doi":"10.1158/1078-0432.ccr-15-0979","pmid":"26251290","year":2015,"roles":["drug_mediator"],"title":"A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma","journal":"Clin Cancer Res","work_id":70714,"publication_date":"2015-08-06"}],"source_paper_count":7,"extracted_claims":[{"side":"drug_mediator","object":"EGFR","context":"in pancreatic ductal adenocarcinoma","subject":"erlotinib","work_id":70714,"claim_id":60909,"polarity":"positive","predicate":"inhibits","confidence":0.9,"extraction_run_id":17},{"side":"drug_mediator","object":"EGFR","context":"in Suit2 and S2-LM7AA pancreatic cancer cells","subject":"erlotinib","work_id":71894,"claim_id":64171,"polarity":"positive","predicate":"inhibits","confidence":0.6,"extraction_run_id":17},{"side":"drug_mediator","object":"EGFR","context":"pancreatic adenocarcinoma","subject":"Erlotinib","work_id":74740,"claim_id":71731,"polarity":"positive","predicate":"inhibits","confidence":0.95,"extraction_run_id":17},{"side":"drug_mediator","object":"EGFR","context":"in pancreatic cancer","subject":"erlotinib","work_id":163119,"claim_id":116778,"polarity":"positive","predicate":"binds_to","confidence":0.9,"extraction_run_id":23},{"side":"drug_mediator","object":"EGFR","context":"in pancreatic ductal adenocarcinoma","subject":"erlotinib","work_id":170142,"claim_id":119062,"polarity":"positive","predicate":"inhibits","confidence":0.9,"extraction_run_id":23},{"side":"drug_mediator","object":"EGFR","context":"in pancreatic cancer","subject":"Erlotinib","work_id":173558,"claim_id":126221,"polarity":"positive","predicate":"inhibits","confidence":0.95,"extraction_run_id":23},{"side":"mediator_outcome","object":"Alzheimer's disease","context":"within the AD protein risk score network in the UK Biobank","subject":"EGFR","work_id":67774,"claim_id":54935,"polarity":"positive","predicate":"associated_with","confidence":0.7,"extraction_run_id":16}],"extracted_claim_count":7,"extraction":{"model":"deepseek-v4-flash","model_source":"configured","prompt_version":"v1_2026_05_07","run_ids":[16,17,23]},"bridge":{"a_to_b_predicate":"inhibits","b_to_c_predicate":"associated_with","a_to_b_evidence_count":6,"b_to_c_evidence_count":1,"edge_support_log_ab":1.9459101490553132,"edge_support_log_bc":0.6931471805599453,"novelty_factor":1.0,"direct_a_to_c_count":0},"embedding":{"model":"bge-m3","dim":1024,"max_length":8192,"similarity_scores":{}},"scoring":{"method":"swanson_abc_log_evidence_with_novelty_penalty","formula":"score = min((log(ab+1) + log(bc+1)) * novelty / 10, 1.0); novelty = 1.0 if direct==0 else 0.7 / (direct+1)","score_raw":0.26390573296152586,"score":0.3958585994422888,"quality_tier":"high","quality_reason":null},"pipeline_run":{"id":4,"run_uuid":"eb8b7730-d92e-4cd5-95dd-95f6c5d62cc2","command":"scripts/backfill_provenance_v2.py:v2_2026_05_12","status":"completed","git_commit":"9996ffaa56e9b7cd5f677bd8203624c2c18aa000","host":"MacBook-Pro-Daniel96.local","started_at":"2026-05-12T21:35:53.363326+00:00","ended_at":"2026-05-12T21:43:41.903387+00:00","notes":"Retroactive provenance backfill on 2026-05-13 for snapshot v2_2026_05_12. Synthetic pipeline_runs row — original generation run records are lost (pre-date provenance schema). All recoverable fields populated from current DB state (claims, works, repurposing_hypotheses); pipeline_run record is synthetic, hence completeness='partial_backfill'.\nBackfilled 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.\nRefreshed 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.\nRefreshed 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.","domains":["als","alzheimer","depression","epilepsy","glioblastoma","inflammatory_bowel_disease","multiple_sclerosis","pancreatic_cancer","rheumatoid_arthritis","type_2_diabetes"]},"generated_at":"2026-05-12T21:43:39.496175+00:00"}